<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811237</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC 2015-04</org_study_id>
    <nct_id>NCT02811237</nct_id>
  </id_info>
  <brief_title>Hospitalization or Out-treatment ManagEment of Patients With Pulmonary Embolism: a Randomized Controlled Trial</brief_title>
  <acronym>HOME-PE</acronym>
  <official_title>Criteria for Hospitalization or Outpatient Management of Patients With Pulmonary Embolism, Hestia Rule Versus Simplified PESI Score : an Open-label Controlled Randomized International Trial (HOME-PE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Georges Pompidou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cliniques universitaires Saint-Luc- Universit√© Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies have demonstrated the possibility of outpatient management or early discharge
      for certain patients presenting acute pulmonary embolism (PE), providing a suitable structure
      is in place.

      The approach featured in the most recent guidelines on acute PE of the European Society of
      Cardiology, refers to an all-cause mortality risk assessment using the Pulmonary Embolism
      Severity Index (PESI) score or the simplified PESI score (sPESI). The sPESI takes into
      account demographics (age), patient history (cancer, cardiac or respiratory disease), and
      clinical data (systolic blood pressure, heart rate, oxygen saturation). Outpatient care is
      offered to low-risk patients, providing that all the conditions pertaining to start
      anticoagulant treatment and follow-up at home are met.

      An alternative approach based on a list of simple criteria has been developed as the one used
      in HESTIA study. The main criteria included in the HESTIA rule consist of absence of the
      following: hemodynamic instability, need for oxygen therapy, high-risk of hemorrhage, renal
      or liver failure, or other medical or social conditions requiring hospitalization.

      The investigators hereby propose comparing these two approaches in an open-label, controlled
      randomized international trial with blinded adjudication of endpoints.

      The main objective is to demonstrate, in normotensive PE patients, that a strategy based on
      the HESTIA rule compared to a strategy based on the simplified PESI score is at least as safe
      as regards the 30-day-rate of adverse events (recurrent VTE, major bleeding or death).

      The major secondary objectives are to demonstrate, in normotensive PE patients, that a
      strategy based on the HESTIA rule compared to a strategy based on the simplified PESI score
      is more effective :

        -  As regards the rate of patients eventually managed as outpatients.

        -  As regards the rate of patients, in theory, eligible for outpatient care,
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients admitted in the Emergency Department of the participating centres and diagnosed
      with PE will be eligible and assessed for potential inclusion.

      Included patients will be randomized into two groups (1:1) and stratified by centre. Data
      will be recorded in a computerized case report form (e-CRF) enabling the randomization.

      The HESTIA group will receive outpatient care proposal based on HESTIA criteria. The sPESI
      group will receive outpatient care proposal based on the simplified PESI score. Any reason
      for management (hospitalization or outpatient treatment) not based on the recommendation will
      be explained and documented in the e-CRF.

      Follow-up will occur within 72 hours after inclusion, at 14 days, 1 month, and 3 months in
      both groups to gather clinical event data (recurrent VTE, major bleeding, death), treatment
      data, unscheduled hospitalizations and patient satisfaction assessment results.

      The major objectives will test HESTIA based strategy versus sPESI based strategy in a
      hierarchical approach:

        -  step 1: non-inferiority analysis on the rate of adverse events,

        -  if yes, step 2: superiority analysis on the rate of patients managed as outpatients,

        -  if yes, step3: superiority analysis on the rate of patients, in theory, eligible for
           outpatient care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of the composite of recurrent VTE, major bleeding and all cause death at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Recurrent VTE: objectively confirmed pulmonary embolism or deep venous thrombosis objectively confirmed.
Major bleeding: according to the International Society on Thrombosis and Haemostasis' criteria.
Death: all-cause mortality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of patients actually managed as outpatients (meaning patients discharged home within 24 hours after the inclusion in the study (first major secondary objective))</measure>
    <time_frame>1 day</time_frame>
    <description>The rate of patients managed as outpatients defined by patients discharged home within 24 hours after the inclusion in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of &quot;low-risk&quot; patients in theory eligible for outpatient care (second major secondary objective)</measure>
    <time_frame>1 day</time_frame>
    <description>The rate of &quot;low-risk&quot; patients eligible for outpatient care:
HESTIA group: patients meeting none of the exclusion criteria of the rule (HESTIA rule negative);
sPESI group: patients with a simplified PESI score =0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints - Rate of cumulative events</measure>
    <time_frame>14 days, 30 days, 90 days</time_frame>
    <description>The rate of the composite of recurrent VTE, major bleeding and all-cause death,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints - Recurrent VTE</measure>
    <time_frame>14 days, 30 days, 90 days</time_frame>
    <description>The rate of recurrent VTE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints - Suspected recurrent VTE</measure>
    <time_frame>14 days, 30 days, 90 days</time_frame>
    <description>The rate of recurrent VTE suspicion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints - Major Bleeding</measure>
    <time_frame>14 days, 30 days, 90 days</time_frame>
    <description>The rate of major bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints - Non major bleeding</measure>
    <time_frame>14 days, 30 days, 90 days</time_frame>
    <description>The rate of non-major clinically relevant bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints - Death</measure>
    <time_frame>14 days, 30 days, 90 days</time_frame>
    <description>The rate of all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints - Serious adverse event</measure>
    <time_frame>14 days, 30 days, 90 days</time_frame>
    <description>The rate of serious adverse event as defined in good clinical practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Applicability of management strategies</measure>
    <time_frame>1 day</time_frame>
    <description>The rate of patients actually managed as outpatients among number of patientpatients eligible for outpatient management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resources utilization</measure>
    <time_frame>Day 90</time_frame>
    <description>Resources utilization will be assessed via the cumulative in-hospital length of stay (LOS) defined as the LOS for initial hospitalization plus LOS of possible unscheduled hospitalizations in the 30 days and 3 months following admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with care</measure>
    <time_frame>30 days</time_frame>
    <description>A specific questionnaire will be used at 30 days following inclusion:
- Anti-Clot Treatment - Specific Questionnaire (ACTS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient quality of life</measure>
    <time_frame>30 days</time_frame>
    <description>A specific questionnaire will be used at 30 days following inclusion:
- Patient-reported Pulmonary Embolism Quality of Life Questionnaire (PEmb-QoL).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1975</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>HESTIA group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sPESI group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HESTIA</intervention_name>
    <description>Management based on the HESTIA rule:
If the rule is negative, meaning that patient meet none of the exclusion criteria of the rule, the proposed management will be outpatient care.
In the other cases, the patient will receive in-hospital care.
Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF.</description>
    <arm_group_label>HESTIA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sPESI</intervention_name>
    <description>Management based on the simplified PESI score:
If the sPESI score =0, the proposed management will be outpatient care.
In the other cases, the patient will receive in-hospital care.
Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF.</description>
    <arm_group_label>sPESI group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission to Emergency Department or unscheduled consultation in one of the
             participating centres;

          -  Symptomatic pulmonary embolism objectively confirmed according to the European Society
             of Cardiology criteria

          -  Insurance cover according to local legislation;

          -  Age ‚â•18 years;

          -  Free informed consent according to local legislation

        Exclusion Criteria:

          -  Shock or hypotension defined as systolic blood pressure &lt;90 mmHg or a systolic
             pressure drop by ‚â•40 mmHg, for &gt;15 minutes, if not caused by new-onset arrhythmia,
             hypovolaemia, or sepsis;

          -  Diagnosis of pulmonary embolism established more than 24H before inclusion;

          -  More than 48h between first presentation to the Emergency unit and inclusion - -
             Factors rendering 30-day follow-up impossible;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Marie ROY, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU d'Angers, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier SANCHEZ, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP H√¥pital Europ√©en Georges Pompidou, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Menno HUISMAN, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center, Leiden, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David JIMENEZ, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramon y Cajal, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andr√©a PENALOZA, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Unisersitaire Saint Luc, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guy MEYER, MD.PhD</last_name>
    <role>Study Chair</role>
    <affiliation>APHP H√¥pital Europ√©en Georges Pompidou, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EriK KLOK, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center Leiden, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier HUGLI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre-Marie ROY, MD.PhD</last_name>
    <phone>06 65 80 66 11</phone>
    <email>PMRoy@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>B√©atrice GABLE</last_name>
    <phone>06 65 80 66 21</phone>
    <email>begable@chu-angers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andr√©a PENALOZA</last_name>
      <email>andrea.penaloza@uclouvain.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H√¥pital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MOTTE Serge</last_name>
      <email>Serge.Motte@erasme.ulb.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H√¥pital Saint-Pierre</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MOLS Pierre</last_name>
      <email>pierre.mols@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Li√®ge</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GHUYSEN Alexandre</last_name>
      <email>a.ghuysen@chu.ulg.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H√¥pital de Namur</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LIEVENS Pascale</last_name>
      <email>pascale.lievens@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Marie ROY, MD-PhD</last_name>
      <phone>06 65 80 66 11</phone>
      <email>pmroy@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hia Brest</name>
      <address>
        <city>Brest</city>
        <zip>29240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne LE COAT</last_name>
      <email>annelecoat@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aur√©lien DELLUC</last_name>
      <email>aurelien.delluc@chu-brest.fr</email>
    </contact>
    <contact_backup>
      <last_name>Francis COUTURAUD</last_name>
      <email>francis.couturaud@chu-brest.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SCHMIDT Jeannot</last_name>
      <email>jschmidt@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle MAHE</last_name>
      <email>isabelle.mahe@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nicolas JAVAUD</last_name>
      <email>nicolas.javaud@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HONNART Didier</last_name>
      <email>didier.honnart@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>FALVO Nicolas</last_name>
      <email>nicolas.falvo@chu-dijon.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime MAIGNAN</last_name>
      <email>MMaignan@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thibault Schott√©</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SCHOTTE Thibault</last_name>
      <email>tschotte@ch-lemans.fr</email>
    </contact>
    <contact_backup>
      <last_name>MONTACLAIR Karine</last_name>
      <email>kmontaclair@ch-lemans.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SEBBANE Mustapha</last_name>
      <email>m-sebbane@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>QUERE Isabelle</last_name>
      <email>i-quere@chu-montpellier.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>APHP Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence DUMAS</last_name>
      <email>florence.dumas@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP H√¥pital Europ√©en Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier SANCHEZ, MD.PhD</last_name>
      <email>olivier.sanchez@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Laure FERAL, MD</last_name>
      <email>anne-laure.feral-pierssens@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>APHP Lariboisi√®re</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Fran√ßois BERGMANN</last_name>
      <email>jf.bergmann@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Patrick PLAISANCE</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JOLY Luc-Marie</last_name>
      <email>Luc-Marie.Joly@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent BERTELOTTI</last_name>
      <email>laurent.bertoletti@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Alain VIALLON</last_name>
      <email>alain.viallon@chuse.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CH Toulon</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ELIAS</last_name>
      <email>antoine.elias@free.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessendra BURA-RIVIERE</last_name>
      <email>bura-riviere.a@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Henry JUCHET</last_name>
      <email>juchet.h@chu-toulouse.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Red Cross Hospital</name>
      <address>
        <city>Beverwijk</city>
        <zip>1942 LE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura l FABER</last_name>
      <email>lfaber@rkz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TERGOOI</name>
      <address>
        <city>Hilversum</city>
        <zip>1213 XZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter Wi KAMPHUISEM</last_name>
      <email>pkamphuisem@tergooi.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center Leiden,</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Menno HUISMAN, MD.PhD</last_name>
      <email>M.V.Huisman@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Erik KLOK, MD</last_name>
      <email>F.A.Klok@lumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde Nijkeuter Nijkeuter</last_name>
      <email>M.Nykeuter@umcutrecht.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ramon y Cajal Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David JIMENEZ, MD.PhD</last_name>
      <email>djimenez.hrc@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H√¥pital de Gen√®ve</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>RIGHINI Marc</last_name>
      <email>Marc.Righini@hcuge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H√¥pital de Lausanne</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HUGLI Olivier</last_name>
      <email>Olivier.Hugli@chuv.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Piran S, Le Gal G, Wells PS, Gandara E, Righini M, Rodger MA, Carrier M. Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis. Thromb Res. 2013 Nov;132(5):515-9. doi: 10.1016/j.thromres.2013.08.012. Epub 2013 Aug 28. Review.</citation>
    <PMID>24035045</PMID>
  </reference>
  <reference>
    <citation>Zondag W, Kooiman J, Klok FA, Dekkers OM, Huisman MV. Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J. 2013 Jul;42(1):134-44. doi: 10.1183/09031936.00093712. Epub 2012 Oct 25.</citation>
    <PMID>23100493</PMID>
  </reference>
  <reference>
    <citation>Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Gali√® N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k. doi: 10.1093/eurheartj/ehu283. Epub 2014 Aug 29. Erratum in: Eur Heart J. 2015 Oct 14;36(39):2666. Eur Heart J. 2015 Oct 14;36(39):2642.</citation>
    <PMID>25173341</PMID>
  </reference>
  <reference>
    <citation>Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, Renaud B, Verhamme P, Stone RA, Legall C, Sanchez O, Pugh NA, N'gako A, Cornuz J, Hugli O, Beer HJ, Perrier A, Fine MJ, Yealy DM. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet. 2011 Jul 2;378(9785):41-8. doi: 10.1016/S0140-6736(11)60824-6. Epub 2011 Jun 22.</citation>
    <PMID>21703676</PMID>
  </reference>
  <reference>
    <citation>Zondag W, Mos IC, Creemers-Schild D, Hoogerbrugge AD, Dekkers OM, Dolsma J, Eijsvogel M, Faber LM, Hofstee HM, Hovens MM, Jonkers GJ, van Kralingen KW, Kruip MJ, Vlasveld T, de Vreede MJ, Huisman MV; Hestia Study Investigators. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost. 2011 Aug;9(8):1500-7. doi: 10.1111/j.1538-7836.2011.04388.x.</citation>
    <PMID>21645235</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

